Frontotemporal dementia with a C9ORF72 expansion in a Swedish family: clinical and neuropathological characteristics.

Landqvist, Maria; Gustafson, Lars; Nilsson, Karin; Traynor, Bryan J; Renton, Alan E; Englund, Elisabet; Passant, Ulla

Published in:
American Journal of Neurodegenerative Disease

2013

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Original Article

Frontotemporal dementia with a C9ORF72 expansion in a Swedish family: clinical and neuropathological characteristics

Maria Landqvist Waldö1, Lars Gustafson1, Karin Nilsson1, Bryan J Traynor3, Alan E Renton3, Elisabet Englund2, Ulla Passant1

1Section of Geriatric Psychiatry, Department of Clinical Sciences, Lund University, Klinikgatan 22, Lund SE-221 85, Sweden; 2Section of Pathology, Department of Clinical Sciences, Lund University, Lund, SE-221 85, Sweden; 3Laboratory of Neurogenetics, NIA, NIH, 35 Convent Drive, Room 1A-1000, Bethesda, MD 20892

Received September 27, 2013; Accepted November 5, 2013; Epub November 29, 2013; Published December 15, 2013

Abstract: Background: In 2011 the C9ORF72 repeat expansion was identified as the most frequent genetic mutation underlying FTD and ALS. The main aim of this study was to investigate clinical characteristics in a large C9ORF72-positive FTD family, and to compare these with the neuropathological findings. Methods: The clinical records of 12 related FTD patients were thoroughly evaluated. The five neuropathologically examined cases were revised using additional TDP-43 immuno-stainings. Four cases were screened for the C9ORF72 expansion. Results: All 12 patients fulfilled the criteria for bvFTD. Restlessness and social neglect were often among the first reported symptoms. Psychotic symptoms were reported in 8 patients. Somatic complaints were seen in 7 cases. All the neuropathologically examined cases were TDP-43 positive. Conclusions: The phenotype of this C9ORF72 hexanucleotide expansion carrier family was bvFTD. The clinical symptom profile was strikingly homogenous. Psychotic symptoms and somatic complaints were observed in most of the cases.

Keywords: Genetics, FTD, longitudinal study, psychotic symptoms, TDP-43

Background

The recently described hexanucleotide repeat expansion in the C9ORF72 gene appears to be the most common genetic cause of familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) [1-3], and has also been found in cases without known family history of dementia [4]. FTD is a heterogeneous group of neurodegenerative diseases affecting predominantly the frontal and temporal brain cortices [5]. Clinically, FTD is divided into three main subtypes: behavioural variant FTD (bvFTD), semantic dementia (SD) and progressive nonfluent aphasia (PNFA) [6]. The association between FTD and the progressive neurological disease ALS has been recognised for many years [7, 8].

A positive family history has been reported in about 40% of FTD cases [9, 10], with an autosomal dominant inheritance pattern in at least 10% of patients [9]. In some families, a co-morbidity with ALS is seen. Genes previously described to carry FTD pathogenic mutations include progranulin (GRN) and microtubule-associated protein tau (MAPT) on chromosome 17, as well as CHMP2B on chromosome 3 [11]. Whereas a mutation in the gene encoding TDP-43 (TARDBP) on chromosome 1 most often causes ALS, in rare cases the phenotype is FTD [12, 13]. With the discovery of the C9ORF72 expansion a strong genetic link between FTD and ALS was found [4, 14].

Since the discovery of the C9ORF72 mutation in 2011 [1, 2], several studies of prevalence [4, 15] as well as clinical and neuropathological features in expansion carriers have been published [16-18].

In a recent large study pathogenic C9ORF72 repeat expansions were observed in about 25% of European familial FTD and about 40% of
familial ALS [4]. In sporadic cases the frequency was highest in Finland, and a Scandinavian origin has been suggested. A Finnish founder risk haplotype has previously been described and was found in the majority of C9ORF72-positive cases, which could support the theory of a common founder [4, 19]. There appears to be large prevalence differences between countries [15]. The prevalence in normal controls based on a large cohort from Great Britain was 0.15% [20].

The mean age at dementia onset in C9ORF72 carriers seems to be around 57 years, albeit with large variability. Penetrance at age 58 is 50%, increasing to almost full penetrance by age 80 [4].

Several publications indicate great heterogeneity in clinical symptomatology associated with C9ORF72 expansion, even within the same family [21-23].

Psychiatric symptoms, particularly psychotic symptoms, have been found as prominent features in patients carrying the C9ORF72 expansion in several studies [17, 21, 23-25]. A possible neuroanatomical basis of neuropsychiatric symptoms in C9ORF72 mutation carriers has been discussed. Involvement of the thalamus and cerebellum has been suggested to be associated with certain symptoms including hallucinations and delusions [21, 23].

Clinical phenotypes of C9ORF72 expansion carriers mainly consist of bvFTD, ALS or FTD with motor neuron disease (FTD-MND). Also, cases that have presented with primary progressive aphasia (PPA) [18, 22], corticobasal and ataxia syndromes [26], Parkinsonism [27], or Alzheimer’s disease [28] have been described.

Neuropathologically, C9ORF72-positive FTD cases exhibit TDP-43 positive inclusions consistent with Mackenzie pathology type A or B [23, 29, 30]. Also, p62-positive inclusions in the cerebellar granule cell layer seem to be specific for this mutation, and are present in most but not all cases [21-23].

A cut-off of 30 or more is commonly used to differentiate between pathogenic or non-pathogenic repeat numbers. There are indications, though, that also expansions between 20 and 30 may be pathogenic [31].

The main aim of the present study was to investigate clinical characteristics including demographic, psychiatric and neurological findings in a genetically characterised family with bvFTD and to compare these results with the neuropathological results.

Materials and methods

We collected clinical and neuropathological data from a large family with a high prevalence of FTD from the southern part of Sweden (Figure 1). The family has been followed at the Department of Psychogeriatrics for over 40 years [32], and we had access to clinical records from 14 family members in three generations (12 with FTD and two at risk-individuals). Also, complementary information was available in public records such as parish records. 5 cases were neuropathologically verified and there was blood available from 4 family members (3 of the autopsy verified cases and 1 case where we only had clinical data). One case has previously been identified as a C9ORF72 expansion carrier [33]. Members of this family have been followed longitudinally for research purposes, making it possible to thoroughly examine them during the course of disease by

![Figure 1. Pedigree of a Swedish family with frontotemporal dementia and a C9ORF72 expansion.](image-url)
repeated clinical evaluations. Neuropsychological assessments and neuroimaging have supported the diagnosis of FTD. Ethical approval for the longitudinal study in which the patients were included was given by the regional ethical review board in Lund.

Clinical evaluations

We retrospectively analysed the clinical records of the 14 family members. All information was carefully read and evaluated by two experienced MDs (MLW, UP), by each observer individually and then once more by both observers together at a consensus meeting.

Demographic data and clinical features including neurological and neuropsychiatric symptoms were noted for each case. Several individuals were diagnosed before publication of the 1998 consensus document and thus all diagnoses were revised and diagnosed as bvFTD according to the Neary et al criteria [6].

The aim was to focus on symptoms not covered by the consensus criteria. Psychiatric features such as psychotic symptoms (hallucinations, delusions, paranoid ideations) and affective symptoms (mood, emotional lability, suicidal ideations, aggression, apathy, restlessness) at any time during the course of the disease were noted. Reported presenting symptoms, which we defined as the first symptoms observed by the family, were noted. Somatic complaints were recorded separately.

Neurological symptoms, including signs of Parkinsonism and motor neuron disease (MND) were evaluated. Symptoms considered as associated with Parkinsonism were rigidity, gait disturbances and tremor. Muscle weakness, loss of ability to walk, exaggerated reflexes, positive primitive reflexes, dysarthria and dysphagia were considered to be possible MND symptoms.

Language symptoms such as decreased speech output, word-finding difficulties, echolalia or perseverations were noted. Special focus was given to symptoms consistent with the earlier described PEMA syndrome (palilalia, echolalia, mutism and amimia) [34]. The patients were considered to suffer from the PEMA syndrome if notes were made about at least 3 out of 4 of the PEMA symptoms in clinical records.

The age at onset was defined as the first time relatives noted symptoms attributable to the disease. Due to large variations in disease duration the terms “early” versus “late” were used to describe when during the disease progression of each individual symptom were noted. In order to define “early” and “late”: if the duration was 16 years, the first 8 years were “early”, and if disease duration was 4 years, then the first 2 years were considered to be “early”.

Pathology

Five cases were neuropathologically examined according to standardised clinical methods at the Pathology Department. The procedure included whole brain assessment with entire bi-hemispheric coronal sections covering all major regions for conventional staining, as described in a previous publication [35].

For comparisons of regionally accentuated pathology, the neocortical areas (frontal, temporal, parietal and occipital cortex) were analysed for severity of degeneration and graded as mild, moderate or severe according to the same definitions as previously published [36].

Particular attention was paid to potential hemispheric asymmetry, but also to pathology in the cerebellum, the thalamus, the hippocampus and regions related to motor function, such as cervical cord motor neurons and upper neurons within the motor cortex. Furthermore, the frontal white matter was assessed with a similar grading. Immunohistochemical staining of phosphorylated TDP-43 and FUS, p62 and phosphorylated tau were analysed. The cases were re-evaluated and revised for confirmation and comparison between the cases. For TDP-43-positive pathology, the pattern of positive inclusions was subtyped according to the Mackenzie system (type A-D) [29], and further semiquantitatively graded 1-4 for increasing severity.

Genetics

Frozen blood samples from 4 individuals within the family (cases II:2, III:10, III:11, III:13) were thawed and DNA was extracted. Also, in two cases (III:3, III:5), DNA was extracted from paraffin-embedded brain material. We screened all samples for the C9ORF72 hexanucleotide.
repeat expansion using the repeat-primed polymerase chain reaction (rpPCR) method previously described [2]. The result was defined as a mutation if this assay consistently showed the characteristic expansion pattern and more than 30 repeats in total.

**Results**

**Clinical findings**

Demographic data is summarised in Table 1. The age at onset (43-70 years) and disease duration (2-21 years) was highly variable within this family. Median age at onset was 60 years and median duration was 10 years.

All cases fulfilled the Neary et al criteria at an early stage, but there were also other symptoms that were prominent in several family members, presented in Table 1.

Psychotic symptoms were seen in 8 of the patients, manifesting as hallucinations, delusions or paranoia. Affective symptoms were frequent, including depression, mood swings, elated mood, emotional lability, suicidal ideations, aggression and restlessness. Apathy, with or without depressed mood, was present in all cases at some time during disease duration, but not as a prominent symptom at an early stage. 4 patients expressed suicidal ideations or suicidal threats but no one committed suicide or made any suicide attempts.

Extreme restlessness in combination with social neglect, defined as loss of social awareness and insight in combination with neglect of self-care, activity of daily living and mismanagement of domestic activities were reported as presenting symptoms in all but one case.

Marked and often persistent pain (head, abdomen, legs) was reported in 7 out of 12 cases and was often present early during the disease or even before disease onset. The patients were subject to repeated medical evaluations due to these symptoms, but in the majority of cases no specific medical explanation for the complaints could be found.

Speech output gradually decreased in all cases, eventually resulting in mutism. In two cases logorrhoea was initially reported. No case had an onset with isolated language impairment. Palilalia, echolalia, mutism and amimia (PEMA) were present in the majority of cases (Table 1).

Hyperphagia was reported in all, and dysphagia in all but one case at some time during the disease. All patients suffered from severe weight loss at the final stage of disease. Dysarthria was noted early in two cases. Motor features were present, to some extent, in all cases. Only one of the cases received the diagnosis MND while alive. When analysed in retrospect, however, symptoms attributable to MND pathology were seen in several individuals (Table 1).

Parkinsonism with rigidity, bradykinesia and gait disturbances, but not tremor, was noted in at least 4 cases, but in only one case this was seen at an early stage of disease. In that particular case symptoms started after the administration of antipsychotic medication and persisted after cessation of the medication. Antipsychotic drugs were administered to 7 patients, all of them reacting with pronounced side effects, in most cases Parkinsonism. Ataxia was not reported in any of the 12 cases.

**Short case reports**

I:1 According to relatives this woman developed dementia many years prior to death. She suffered from a stroke during her last year of life, and died at the age of 88.

I:2 The husband of I:1 died at age 49, according to parish registration cause of death was “cardiac paralysis”.

II:2 The personality and behaviour of this woman changed markedly at the age of 57. She became restless, disinhibited and acted socially inappropriately, by paying visits to unknown people, laughing, telling jokes and confabulating. She also ignored self-care and domestic activities. Memory, recognition and spatial skills were preserved, however she developed speech disturbances with severe logorrhoea followed by reduced speech output. She made suicidal threats. Already after two years she could no longer be taken care of at home. When given antipsychotic drugs she developed extreme Parkinsonism and the negative side effects lasted for months, even after medication was withdrawn.

II:3 According to relatives this woman had a 10 year history of progressive dementia before
Table 1. Clinical features of a Swedish family with frontotemporal dementia and a C9ORF72 expansion

<table>
<thead>
<tr>
<th>Case</th>
<th>Onset (y)</th>
<th>Duration (y)</th>
<th>Psychotic symptoms</th>
<th>Affective symptoms</th>
<th>Somatic complaints</th>
<th>PEMA</th>
<th>Dysarthria</th>
<th>Dysphagia</th>
<th>Motor features</th>
<th>Antipsychotic drugs</th>
<th>Reported presenting symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>II:2</td>
<td>57</td>
<td>12</td>
<td>Paranoid ideations, delusions</td>
<td>Elated/depressed mood, suicidal threats, aggression</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Early</td>
<td>Early Parkinsonism, muscle atrophy, incontinence</td>
<td>Yes, pronounced rigidity, even after medication stopped</td>
<td>Social neglect*, restlessness</td>
</tr>
<tr>
<td>II:3</td>
<td>64</td>
<td>10</td>
<td>Tactile halluc.</td>
<td>Elated/depressed mood, suicidal threats</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Late</td>
<td>Late Parkinsonism, falls, incontinence</td>
<td>Yes, rigidity</td>
<td>Social neglect, restlessness, memory problems</td>
</tr>
<tr>
<td>II:4</td>
<td>65</td>
<td>21</td>
<td>NA</td>
<td>Aggression</td>
<td>NA</td>
<td>No speech</td>
<td>NA</td>
<td>NA</td>
<td>Muscle atrophy</td>
<td>No</td>
<td>Restlessness, aggression</td>
</tr>
<tr>
<td>II:5</td>
<td>55</td>
<td>6</td>
<td>Aud, halluc., delusions</td>
<td>Emotional lability, elated/depressed mood, suicidal threats, aggression</td>
<td>Pain (legs)</td>
<td>Yes</td>
<td>No</td>
<td>Late</td>
<td>Social neglect, restlessness, emotional lability/suicidal threats, psychotic symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III:2</td>
<td>68</td>
<td>3</td>
<td>Visual halluc., delusions, paranoid ideations</td>
<td>Emotional lability, aggression</td>
<td>Pain (head, abdominal, legs)</td>
<td>Yes</td>
<td>Early</td>
<td>Early</td>
<td>MND, falls</td>
<td>No</td>
<td>Restlessness, paranoid ideations, aggression, motoric symptoms</td>
</tr>
<tr>
<td>III:3</td>
<td>50</td>
<td>5</td>
<td>Delusions, visual/aud halluc.</td>
<td>Paranoid ideations</td>
<td>Emotional lability, depression mood</td>
<td>Pain (head, chest)</td>
<td>Yes</td>
<td>Early</td>
<td>Early</td>
<td>Exaggerated reflexes</td>
<td>Yes, lost ability to speak</td>
</tr>
<tr>
<td>III:5</td>
<td>46</td>
<td>17</td>
<td>Paranoid ideations, suicidal ideations</td>
<td>Emotional lability</td>
<td>Pain (abdominal)</td>
<td>Yes</td>
<td>No</td>
<td>Late</td>
<td>Late Parkinsonism, incontinence</td>
<td>Yes, pronounced rigidity, salivation</td>
<td>Restlessness, inappropriate behaviour</td>
</tr>
<tr>
<td>III:8</td>
<td>69</td>
<td>10</td>
<td>No</td>
<td>Emotional lability</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Early</td>
<td>Bradykinesia, incontinence</td>
<td>No</td>
<td>Social neglect, restlessness, emotional lability</td>
</tr>
<tr>
<td>III:10</td>
<td>68</td>
<td>5</td>
<td>No</td>
<td>Aggression</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Late</td>
<td>Exaggerated reflexes</td>
<td>Yes, pronounced tiredness</td>
<td>Social neglect, inappropriate relationships</td>
</tr>
<tr>
<td>III:11</td>
<td>52</td>
<td>18</td>
<td>Paranoid ideations, suicidal ideations</td>
<td>Emotional lability</td>
<td>Pain (head, abdominal)</td>
<td>Yes</td>
<td>No</td>
<td>Early</td>
<td>Late Parkinsonism, falls</td>
<td>Yes, salivation</td>
<td>Social neglect, restlessness, anxiety, suicidal thoughts, paranoid ideations</td>
</tr>
<tr>
<td>III:12</td>
<td>70</td>
<td>2</td>
<td>NA</td>
<td>Emotional lability</td>
<td>Pain (head, abdominal)</td>
<td>2/4 criteria</td>
<td>No</td>
<td>Late</td>
<td>Muscle atrophy, exaggerated reflexes, gait disturbance, falls</td>
<td>No</td>
<td>Apathy, anxiety</td>
</tr>
<tr>
<td>III:13</td>
<td>43</td>
<td>17</td>
<td>Visual/tactile halluc.</td>
<td>Emotional lability, aggression</td>
<td>Pain (head, abdominal)</td>
<td>Yes</td>
<td>Late</td>
<td>No</td>
<td>Incontinence</td>
<td>Yes, deterioration</td>
<td>Social neglect, restlessness, aggression, alcohol abuse</td>
</tr>
</tbody>
</table>

Abbreviations: PEMA=palilalia, echolalia, mutism and amimia; MND=motor neuron disease; aud.=auditory; halluc.=hallucinations; NA=not applicable, insufficient clinical data; Bold=neuropathologically verified cases. *The term social neglect is defined as loss of social awareness and insight in combination with neglect of self-care, ADLS and mismanagement of domestic activities.

Table 2. Brain pathology in neuropathologically verified cases

<table>
<thead>
<tr>
<th>Case</th>
<th>Onset</th>
<th>Duration</th>
<th>Front cx</th>
<th>Temp cx</th>
<th>Pariet cx</th>
<th>Hipp</th>
<th>Nigra</th>
<th>Thalamus</th>
<th>Cerebellum</th>
<th>White matter, frontal</th>
<th>pTDP-43</th>
<th>Asymmetry</th>
<th>Weight (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>III:3</td>
<td>50</td>
<td>5</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>R=L</td>
<td>1280</td>
</tr>
<tr>
<td>III:5</td>
<td>46</td>
<td>15</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
<td>4</td>
<td>R=L</td>
</tr>
<tr>
<td>III:10</td>
<td>68</td>
<td>5</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>0</td>
<td>++</td>
<td>R&gt;l</td>
</tr>
<tr>
<td>III:11</td>
<td>52</td>
<td>18</td>
<td>+++*</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>+++</td>
<td>4</td>
<td>R&gt;l</td>
</tr>
<tr>
<td>III:13</td>
<td>43</td>
<td>17</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>+++</td>
<td>+</td>
<td>++</td>
<td>3</td>
<td>R=L</td>
</tr>
</tbody>
</table>

Abbreviations: Front cx=frontal cortex; Temp cx=temporal cortex; Pariet cx=parietal cortex; Nigra=substantia nigra; pTDP-43=phosphorylated tar DNA binding protein-43. R=right, L=left. *Extra severe degeneration, exceeding all other graded areas.
Dying at age 74. She was admitted to the Department of Psychogeriatrics 4 years prior to death with severe agitation, restlessness and tactile hallucinations. Her speech was sparse with echolalia. Utilisation behaviour [37] was a prominent symptom. On low doses of antipsychotic drugs she displayed Parkinsonism and made no verbal contact. She often fell and during the last two years of life she was unable to walk. She died from heart failure.

II:4 This woman lived isolated in a cottage in the forest. It was reported that she had undergone a marked personality change during the last two decades of life. At the age of 85 she suffered from a stroke that left her hemiplegic on the left side. At that time it was noted she was mute.

II:5 At the age of 55 this mother of nine changed in personality. She became restless, neglected her home and family, showed an affective lability, stated suicidal threats and had auditory hallucinations. For a certain period of time she showed an elated mood with inappropriate singing and dancing. Speech output decreased and she showed perseverations. Utilisation behaviour and physical aggressiveness were noted.

III:2 This woman had a long history of diffuse somatic complaints (headache, vertigo), being subjected to repeated medical evaluations beginning at age 35. At the age of 68 her personality changed. She showed aggression and suspicions towards her husband, became restless and emotionally incontinent. She spent large amounts of money on unnecessary items with no thoughts of economic consequences. Visual hallucinations were present. She developed dysarthria, dysphagia and progressive muscle weakness, and was wheelchair ridden 2 years after onset. She died of pneumonia one year later.

III:3 This woman’s husband reported a change in her personality when she was 50 years old. She became restless and uninterested about herself and domestic activities, showed an affective lability and aggression. She reported visual hallucinations and started to confabulate. Her speech changed rapidly to stereotyped phrases and echolalia. Her ability to find words was severely impaired when given antipsychotic drugs. She died from aspiration of a large piece of food.

III:5 This man had several depressive episodes with suicidal thoughts but also paranoid ideas and suspiciousness starting in his mid-forties. He neglected his family. He continued to work for another 10 years after onset even after being diagnosed with cerebral atrophy. He showed a profound restlessness and often changed jobs. Disinhibition and compulsive behaviour were noticed. He was involved in several traffic accidents. He presented an array of somatic complaints mainly located to his abdomen and consulted many different physicians. No somatic reason for his complaints could be found. His spontaneous language gradually decreased and before reaching total mutism it consisted of only a limited number of stereotypical phrases. In contrast to the other affected family members he was still able to walk until he died after 17 years.

III:8 In her late sixties this woman changed in personality and neglected her home and family. She was restless and showed emotional lability. Her spontaneous speech gradually decreased. Clinical information about the last years of her life is limited.

III:10 The family of this woman reported a marked personality change at the age of 68, when she started to reply to contact advertisements and made several new acquaintances of inappropriate character. She became extremely restless. Early speech disturbances were noticed with severe logorrhoea followed by stereotyped phrases and reduced speech output. She died of pneumonia.

III:11 At the age of 52 this woman started to neglect her home and family. She was restless, anxious and preoccupied with somatic symptoms. According to relatives she mentioned suicidal thoughts and had paranoid ideas. Language impairment was seen early with stereotyped phrases and later dominated by echolalia. She was involved in several traffic incidents due to lack of judgement. During the last 7 years in life she was mute and bedridden.

III:12 In her early seventies this woman was severely demented. There is however limited information about the early stages of disease, but according to relatives she had gradually become restless and later apathetic. Her language deteriorated with perseverations and reduced output. She complained about pains in...
FTD with a C9ORF72 expansion in a Swedish family

head and abdomen. Motor features included a tendency to fall.

III:13 At the age of 43 this man changed in personality and behaviour. He became apathetic and no longer showed any interest in his family. He became quarrelsome with physical aggressiveness. His lack of insight and disinhibition led to shoplifting and impulsive economic transactions. Tactile and visual hallucinations with social consequences were present. His speech consisted of stereotyped phrases and echolalia. He complained about headache, abdominal and back pain.

Brain pathology

All five cases that were neuropathologically examined showed TDP-43 type B positive pathology with all cortical layers involved, few dystrophic neurites and few to moderate numbers of cellular inclusions (NCI) (Figure 2). A prominent feature, however, was that of intra-neuronal granular positivities (not dense and delineated inclusions) in all cases - in those cases exhibiting most severe TDP pathology it was abundant. Staining with the p62 antibody revealed neuronal inclusions and fine granular positivities in the neocortex.

The severity of overall degeneration varied from mild to severe pathology, seemingly in parallel with the severity of TDP-43 pathology and with disease duration (Table 2). All cases had predominantly frontotemporal pathology, either symmetric (3 cases) or predominantly right-sided (2 cases). The single case with marked brain atrophy (870 g) exhibited the most severe brain pathology and had the longest disease duration, whereas in four of the five cases, brain weight was within relatively normal limits (1130-1330 g), irrespective of disease severity, duration and age of onset. In the individual with brain weight of 1330 g, however, there was a final hypoxic oedema and congestion, probably contributing to the reported brain weight.

The substantia nigra exhibited neuronal loss and depigmentation in all cases, more severely in the two individuals displaying Parkinsonism.

The thalamus revealed neuronal loss and gliosis in four of the five cases. Among these, three showed psychotic symptoms. The patient without discernible thalamus changes displayed hallucinations and delusions.

Motor areas pertinent to MND features, such as cervical cord anterior motor neurons and the upper motor neurons of the postcentral neocortex, showed loss of or at least degeneration with atrophy of neurons in these regions. Due to dissimilar sampling over the years, only the postcentral motor cortex was represented in all cases, whereas cervical cord sections were available in only two of the cases.

Genetic findings

Cases III:2, III:10, III:11, III:13 all carried an pathogenic expansion in C9ORF72. The rpPCR analysis of DNA derived from paraffin-embedded material failed.

Discussion

In this study we provide a detailed analysis of the clinical features for 12 related individuals in a family with bvFTD and the C9ORF72 mutation, as well as describing the brain changes in 5 individuals. We highlight the degree of similarity and differences in clinical and neuropathological features in this large family with the newly discovered genetic abnormality. The particular approach of this longitudinal study is the description of a very thoroughly documented family with an autosomal dominant inheritance pattern. In contrast to other publications claiming great phenotypic heterogeneity even within families carrying the C9ORF72 expansion, we found that clinical presentations in this

Figure 2. Immunohistochemical Tau DNA-binding protein (TDP-43) staining from the anterior frontal lobe, showing features of TDP-43 type B pathology according to Mackenzie et al., including neuronal cytoplasmic inclusions (a) and few short dystrophic neurites (b).
family are strikingly similar, although age at onset and duration are highly variable.

Psychiatric symptoms including a profound restlessness, social neglect and affective symptoms were prominent features in this family, being among the earliest noted symptoms in the majority of cases. Psychotic symptoms have previously been described as a conspicuous feature in up to 50% of C9ORF72 carriers [21] and this is supported by the findings in our family. It has been suggested that thalamic and cerebellar projections could be related to the neuropsychiatric features associated with this mutation, including hallucinations and/or delusions [23]. However in our material, thalamic pathology was seen both in cases with and without psychotic symptoms.

None of our patients exhibited any positive effects from antipsychotic drugs. On the contrary, they all suffered from severe side effects that in some cases did not reverse after withdrawal of medication. This is in line with previous reports that FTD constitutes a group with marked vulnerability to pharmacological interventions [38]. All post mortem cases examined displayed degeneration of the substantia nigra. Thus, we cannot conclude to what extent the observed parkinsonian features are related to nigral degeneration or to pharmacologic side effects, or both.

The majority of patients exhibited somatic complaints such as pain, predominantly headache or abdominal pain, not supported by objective findings. It is difficult, though, to know the nature of these complaints, if there is a true organic background such as central pathology (i.e. involvement of the thalamus leading to altered pain experience) or unidentified changes in the peripheral neural system, or if they should be considered somatic delusions as discussed in earlier studies [21]. This matter needs to be studied in a larger case series. In a Brazilian kindred co-morbidity with inflammatory bowel disease was reported in 2 cases [39]. In our family several individuals complained about abdominal pain, and also had repeated medical examinations as a result. No patient was diagnosed with inflammatory bowel disease.

One speculative hypothesis on the high prevalence of FTD in this family (more than 50% of generations 2 and 3) is the possibility that both parents in generation I may have been carriers of the C9ORF72 expansion. Genealogical research has shown that they both came from the same village. Another hypothesis may be that there are as yet unidentified modifying genes, resulting in a high vulnerability for this disease.

The prevailing opinion is that expansions of >30 repeats are pathological, but there is also one publication indicating that 20-30 repeats might also cause disease [31]. All four analysed cases in our family had >30 repeats. As this analysis included only a small number of cases it was not possible to make any conclusions regarding the exact number of repeats and, for example, demographic data. Thus the exact size of the expansions were not analysed by Southern blot. Other studies have not found any correlation between expansion size and age at onset or disease duration, but they have screened large cohorts for C9ORF72 expansions without looking at several related individuals [40].

Limitations of this study are the retrospective design with its inherent difficulty to assess reported symptoms based on clinical notes and that we did not have DNA and neuropathological data from all individuals. It is also possible that information about certain symptoms may not have been mentioned in the clinical records, thereby resulting in the underestimation of these. However, the affected family members had been followed thoroughly by repeated clinical evaluations and the disease course was very well documented in the majority of cases.

Summarising our findings, they demonstrate the importance of longitudinal follow up in familial neurodegenerative disease. Some individuals may progress extremely slowly and although the clinical picture is very similar between the family members some differences should not be neglected. Considering the variation in age at onset and disease duration there might be other factors than the C9ORF72 expansion yet to be revealed which contribute to the clinical picture and disease course.

Acknowledgements

This study was supported by the Council of Region Skåne, Demensfonden, the Sjöbring
Foundation and the Trolle-Wachtmeister Foundation. The authors wish to thank Annette Persson for her contribution to the project.

Disclosure of conflict of interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Address correspondence to: Dr. Maria Landqvist
Waldö, Section of Geriatric Psychiatry, Department of Clinical Sciences, Lund University, Klinikgatan 22, Lund SE-221 85, Sweden. E-mail: maria.landqvist@med.lu.se

References


[11] Sleeegers K, Cruts M and Van Broeckhoven C. Molecular pathways of frontotemporal lobar...
FTD with a C9ORF72 expansion in a Swedish family


FTD with a C9ORF72 expansion in a Swedish family


